Historical data suggests the sector outperforms after midterm elections. And Democrats, newly in control of Congress, have ...
The decision sparked a sell-off in Nurix shares as well as analyst debate about the prospects of drugs designed to degrade a ...
The breakup, which will separate Aetna and Caremark from CVS’ retail pharmacies, is an indictment of the dogma that bigger is ...
AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears ...
On a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall ...
The FDA appears likely to hold an advisory committee for UniQure’s closely watched Huntington’s disease gene therapy. Elsewhere, a biotech’s share price was cut in half following a regulatory setback.
Explore how integrated scenario modeling helps pharma leaders navigate pricing uncertainty and the complexity of global ...
The health policy think tank urged seniors to shop carefully for prescription drug coverage during Medicare open enrollment, given skyrocketing premiums and wide variance in costs between plans.
Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood ...
The San Diego biotechnology startup is one of several firms working on a cutting-edge technique with the potential to slow or ...
The parent of cell therapy maker Gamida Cell will be the lead bidder in a court-supervised auction of Karyopharm, which ...
At one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results